drugset / Trial / NCT07587788

RBD5044 in Chinese Participants With Hypertriglyceridemia

NCT07587788 ↗

Phase 2 Recruiting 40 enrolled Ribotek Biopharmaceuticals (Shandong) Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat hypertriglyceridemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84).

Timeline

Start
2026-02-28
Primary completion
2027-03
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RBD5044 Unknown — Subcutaneous

Indications